نمایش مختصر رکورد

dc.contributor.authorMehraji, Zahraen_US
dc.contributor.authorFarazmand, Alien_US
dc.contributor.authorEsteghamati, Alirezaen_US
dc.contributor.authorNoshad, Sinaen_US
dc.contributor.authorSadr, Maryamen_US
dc.contributor.authorAmirzargar, Somayehen_US
dc.contributor.authorYekaninejad, Mir Saeeden_US
dc.contributor.authorAmirzargar, Aliakbaren_US
dc.date.accessioned1399-07-09T07:49:11Zfa_IR
dc.date.accessioned2020-09-30T07:49:11Z
dc.date.available1399-07-09T07:49:11Zfa_IR
dc.date.available2020-09-30T07:49:11Z
dc.date.issued2017-09-01en_US
dc.date.issued1396-06-10fa_IR
dc.date.submitted2017-09-18en_US
dc.date.submitted1396-06-27fa_IR
dc.identifier.citationMehraji, Zahra, Farazmand, Ali, Esteghamati, Alireza, Noshad, Sina, Sadr, Maryam, Amirzargar, Somayeh, Yekaninejad, Mir Saeed, Amirzargar, Aliakbar. (2017). Association of Human Leukocyte Antigens Class I & II with Graves’ Disease in Iranian Population. Iranian Journal of Immunology, 14(3), 223-230.en_US
dc.identifier.issn1735-1383
dc.identifier.issn1735-367X
dc.identifier.urihttps://iji.sums.ac.ir/article_39312.html
dc.identifier.urihttps://iranjournals.nlai.ir/handle/123456789/329511
dc.description.abstract<strong>Background</strong>: Graves' disease (GD), a highly rampant autoimmune disorder of the thyroid gland, is responsible for 60-80% of the clinical cases of hyperthyroidism. Over the past decades, genetic association studies have identified several GD susceptibility loci in CTLA-4, TSHR and major histocompatibility complex regions. The information on the association between the human leukocyte antigens (HLA) and GD among Iranians is scarce. <strong>Objective</strong>: To identify HLA polymorphisms that might confer susceptibility or protect against GD. <strong>Methods</strong>: Eighty unrelated patients with a confirmed diagnosis of GD were included in the case group. The control group consisted of 180 unrelated healthy individuals with normal thyroid function tests. The polymerase chain reaction with sequence specific primers (PCR-SSP) method was used for HLA typing. <strong>Results:</strong> Frequencies of HLA-A*68 (15.6% vs. 4.2%, p=0.004) and B*08 (8.8% vs. 2.5, p=0.030) were significantly higher in patients with GD compared with healthy controls. No patients with GD had HLA-A*33, whereas it was found in 7.0% of the controls (p=0.011). HLA-DQB1*0201 was significantly less frequent among patients with GD (15.6% vs. 26.8%, p=0.040). Additionally, patients with GD were significantly less bound to have HLA-DQA1*0201 (6.2% vs. 15.1%, p=0.045). Concerning allelic distributions, no noticeable difference was found between GD patients with and without Graves' ophthalmopathy (p>0.05 in all cases). <strong>Conclusion</strong>: In the Iranian population, HLA-A*68 and -B*08 confer susceptibility to GD, whereas HLA-A*33, -DQB1*0201, and -DQA1*0201 appear to have protective roles.en_US
dc.languageEnglish
dc.language.isoen_US
dc.publisherShiraz Institute for Cancer Researchen_US
dc.relation.ispartofIranian Journal of Immunologyen_US
dc.subjectAssociationen_US
dc.subjectGraves' Diseaseen_US
dc.subjectGraves' ophthalmopathyen_US
dc.subjectHLAen_US
dc.subjectPolymorphismen_US
dc.subjectIranen_US
dc.titleAssociation of Human Leukocyte Antigens Class I & II with Graves’ Disease in Iranian Populationen_US
dc.typeTexten_US
dc.typeOriginal Articleen_US
dc.contributor.departmentDepartment of Cellular and Molecular Biology, Kish International Campus, University of Tehran, Kish Island, Iranen_US
dc.contributor.departmentDepartment of Cellular and Molecular Biology, Faculty of Science, University of Tehran, Tehran, Iranen_US
dc.contributor.departmentEndocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iranen_US
dc.contributor.departmentEndocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iranen_US
dc.contributor.departmentMolecular Immunology Research Center and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iranen_US
dc.contributor.departmentMolecular Immunology Research Center and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iranen_US
dc.contributor.departmentDepartment of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iranen_US
dc.contributor.departmentMolecular Immunology Research Center and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iranen_US
dc.citation.volume14
dc.citation.issue3
dc.citation.spage223
dc.citation.epage230
nlai.contributor.orcid0000-0002-7442-2519


فایل‌های این مورد

فایل‌هااندازهقالبمشاهده

فایلی با این مورد مرتبط نشده است.

این مورد در مجموعه‌های زیر وجود دارد:

نمایش مختصر رکورد